The Clorox Company (NYSE:CLX) Stock Position Raised by Slow Capital Inc.

Slow Capital Inc. increased its stake in The Clorox Company (NYSE:CLX - Free Report) by 90.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,210 shares of the company's stock after acquiring an additional 16,748 shares during the period. Slow Capital Inc.'s holdings in Clorox were worth $5,185,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of CLX. Norges Bank purchased a new position in shares of Clorox during the fourth quarter worth about $259,041,000. FMR LLC boosted its holdings in Clorox by 75.4% in the 4th quarter. FMR LLC now owns 1,361,758 shares of the company's stock valued at $221,163,000 after purchasing an additional 585,526 shares in the last quarter. KBC Group NV boosted its holdings in Clorox by 688.7% in the 1st quarter. KBC Group NV now owns 587,679 shares of the company's stock valued at $86,535,000 after purchasing an additional 513,171 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Clorox by 549.8% during the 4th quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock valued at $88,144,000 after acquiring an additional 459,203 shares during the period. Finally, ExodusPoint Capital Management LP lifted its position in shares of Clorox by 187.9% during the 4th quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock valued at $113,508,000 after acquiring an additional 456,114 shares during the period. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Clorox Stock Performance

CLX traded up $2.02 on Thursday, hitting $128.92. 584,774 shares of the company's stock were exchanged, compared to its average volume of 1,417,517. The firm has a market cap of $15.89 billion, a PE ratio of 23.14, a P/E/G ratio of 3.06 and a beta of 0.51. The Clorox Company has a twelve month low of $117.35 and a twelve month high of $171.37. The stock has a fifty day moving average of $127.65 and a two-hundred day moving average of $141.81. The company has a current ratio of 0.74, a quick ratio of 0.44 and a debt-to-equity ratio of 13.07.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. During the same quarter last year, the company earned $1.71 EPS. Clorox's revenue was down 8.0% compared to the same quarter last year. On average, research analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CLX. Jefferies Financial Group cut their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. JPMorgan Chase & Co. lowered their price objective on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Wells Fargo & Company lowered their price objective on shares of Clorox from $142.00 to $135.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 9th. Morgan Stanley decreased their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, Citigroup reaffirmed a "neutral" rating and set a $135.00 price target (down from $140.00) on shares of Clorox in a research report on Tuesday. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, Clorox has a consensus rating of "Hold" and an average target price of $145.17.

Insider Buying and Selling

In related news, Director Pierre R. Breber acquired 4,000 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director directly owned 4,000 shares of the company's stock, valued at approximately $546,280. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.57% of the company's stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.